PET Study of a2a Agonist Effects on the Ventricular CSF Clearance of [11C]Butanol
Status:
Withdrawn
Trial end date:
2021-05-24
Target enrollment:
Participant gender:
Summary
This investigator initiated, pilot study will assess the feasibility of characterizing the
effects of an orally administered alpha-2 adrenergic (a2a) agonist, clonidine, on the
clearance rates of Carbon-11 butanol from the ventricular cerebrospinal fluid (vCSF) with
positron emission tomography (PET) in healthy volunteers.